410 related articles for article (PubMed ID: 19188744)
1. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.
Lammoglia JJ; Mericq V
Horm Res; 2009; 71(3):178-84. PubMed ID: 19188744
[TBL] [Abstract][Full Text] [Related]
2. Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms.
Finer G; Price HE; Shore RM; White KE; Langman CB
Am J Med Genet A; 2014 Jun; 164A(6):1545-9. PubMed ID: 24668887
[TBL] [Abstract][Full Text] [Related]
3. Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?
Claramunt-Taberner D; Bertholet-Thomas A; Carlier MC; Dijoud F; Chotel F; Silve C; Bacchetta J
Pediatr Nephrol; 2018 Jul; 33(7):1263-1267. PubMed ID: 29594503
[TBL] [Abstract][Full Text] [Related]
4. The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.
Garringer HJ; Fisher C; Larsson TE; Davis SI; Koller DL; Cullen MJ; Draman MS; Conlon N; Jain A; Fedarko NS; Dasgupta B; White KE
J Clin Endocrinol Metab; 2006 Oct; 91(10):4037-42. PubMed ID: 16868048
[TBL] [Abstract][Full Text] [Related]
5. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
Dumitrescu CE; Kelly MH; Khosravi A; Hart TC; Brahim J; White KE; Farrow EG; Nathan MH; Murphey MD; Collins MT
Osteoporos Int; 2009 Jul; 20(7):1273-8. PubMed ID: 18982401
[TBL] [Abstract][Full Text] [Related]
6. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene.
Ichikawa S; Imel EA; Sorenson AH; Severe R; Knudson P; Harris GJ; Shaker JL; Econs MJ
J Clin Endocrinol Metab; 2006 Nov; 91(11):4472-5. PubMed ID: 16940445
[TBL] [Abstract][Full Text] [Related]
7. Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in
Kışla Ekinci RM; Gürbüz F; Balcı S; Bişgin A; Taştan M; Yüksel B; Yılmaz M
J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):94-99. PubMed ID: 30015621
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
Rafaelsen S; Johansson S; Ræder H; Bjerknes R
BMC Genet; 2014 Sep; 15():98. PubMed ID: 25249269
[TBL] [Abstract][Full Text] [Related]
9. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.
Benet-Pagès A; Orlik P; Strom TM; Lorenz-Depiereux B
Hum Mol Genet; 2005 Feb; 14(3):385-90. PubMed ID: 15590700
[TBL] [Abstract][Full Text] [Related]
10. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
Ichikawa S; Guigonis V; Imel EA; Courouble M; Heissat S; Henley JD; Sorenson AH; Petit B; Lienhardt A; Econs MJ
J Clin Endocrinol Metab; 2007 May; 92(5):1943-7. PubMed ID: 17311862
[TBL] [Abstract][Full Text] [Related]
11. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.
Araya K; Fukumoto S; Backenroth R; Takeuchi Y; Nakayama K; Ito N; Yoshii N; Yamazaki Y; Yamashita T; Silver J; Igarashi T; Fujita T
J Clin Endocrinol Metab; 2005 Oct; 90(10):5523-7. PubMed ID: 16030159
[TBL] [Abstract][Full Text] [Related]
12. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
Folsom LJ; Imel EA
Curr Osteoporos Rep; 2015 Apr; 13(2):78-87. PubMed ID: 25656441
[TBL] [Abstract][Full Text] [Related]
13. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.
Ichikawa S; Imel EA; Kreiter ML; Yu X; Mackenzie DS; Sorenson AH; Goetz R; Mohammadi M; White KE; Econs MJ
J Clin Invest; 2007 Sep; 117(9):2684-91. PubMed ID: 17710231
[TBL] [Abstract][Full Text] [Related]
14. Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23.
Ito N; Fukumoto S
Calcif Tissue Int; 2021 Jan; 108(1):104-115. PubMed ID: 31965220
[TBL] [Abstract][Full Text] [Related]
15. A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis.
Masi L; Gozzini A; Franchi A; Campanacci D; Amedei A; Falchetti A; Franceschelli F; Marcucci G; Tanini A; Capanna R; Brandi ML
J Bone Joint Surg Am; 2009 May; 91(5):1190-8. PubMed ID: 19411468
[TBL] [Abstract][Full Text] [Related]
16. Use of Teriparatide in Hyperphosphatemic Familial Tumor Calcinosis: Evaluating the Interaction Between FGF23 and PTH on the Phosphaturic Effect.
Pallone SG; Kunii IS; da Silva REC; Lazaretti-Castro M
Calcif Tissue Int; 2022 Jul; 111(1):102-106. PubMed ID: 35338393
[TBL] [Abstract][Full Text] [Related]
17. Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.
Chakhtoura M; Ramnitz MS; Khoury N; Nemer G; Shabb N; Abchee A; Berberi A; Hourani M; Collins M; Ichikawa S; El Hajj Fuleihan G
Osteoporos Int; 2018 Sep; 29(9):1987-2009. PubMed ID: 29923062
[TBL] [Abstract][Full Text] [Related]
18. Dialysis as a Treatment Option for a Patient With Normal Kidney Function and Familial Tumoral Calcinosis Due to a Compound Heterozygous FGF23 Mutation.
Goldenstein PT; Neves PD; Balbo BE; Elias RM; Pereira AC; Onuchic LF; Jüppner H; Jorgetti V; Abensur H; Moysés RM
Am J Kidney Dis; 2018 Sep; 72(3):457-461. PubMed ID: 29548779
[TBL] [Abstract][Full Text] [Related]
19. The role of bone in phosphate metabolism.
Fukumoto S
Mol Cell Endocrinol; 2009 Oct; 310(1-2):63-70. PubMed ID: 18822343
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
